Patents by Inventor Gerhard Winter

Gerhard Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10723762
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Publication number: 20200004230
    Abstract: A production planning system (6) for a raw materials industry plant (ANL), which determines the production planning data (Pi) thereof and specifies said data to the automation system (1) of the plant (ANL). A state monitoring system (7) determines previous and future anticipated states (Z1) of components of the plant (ANL). A quality determination system (8) determines states (Z2) of output products (Ai) produced and still to be produced by the plant (ANL) and/or past and future states (Z3) of the plant (ANL) as a whole. A maintenance planning system (9) and/or the production planning system (6) receive, from the state monitoring system (7), the states (Z1) of the components of the plant (ANL), determined by the state monitoring system (7) and, from the quality determination system (8), the states (Z2 and Z3) of the output products (Ai) and/or of the plant (ANL) as a whole, determined by the quality determination system (8).
    Type: Application
    Filed: January 30, 2018
    Publication date: January 2, 2020
    Inventors: Kai ANKERMANN, Arno HASCHKE, Kurt HERZOG, Gerhard KURKA, Michael WEINZINGER, Günther WINTER
  • Publication number: 20190161522
    Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.
    Type: Application
    Filed: June 13, 2017
    Publication date: May 30, 2019
    Inventors: Lin ROMER, Ute SLOTTA, Julia ENGERT, Gerhard Winter, Matthias Lucke, Thomas Scheibel
  • Publication number: 20170305964
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 26, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Publication number: 20170202995
    Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 20, 2017
    Inventors: Gerhard Winter, Elisa Agostini, Julia Engert, Lin Romer, Ute Slotta
  • Patent number: 9657054
    Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: May 23, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Patent number: 9504760
    Abstract: The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: November 29, 2016
    Inventors: Sebastian Fuchs, Conrad Coester, Heidrun Gehlen, John Klier, Gerhard Winter
  • Publication number: 20160228368
    Abstract: The present patent application relates to a pharmaceutical product and a device for the storage, handling, transport and administration of active ingredients, pharmaceutical formulations and vaccines. In addition, the present invention relates to a device and pharmaceutical product suitable for intra-dermal, intra-mucosal or epidermal administration like for example intra-dermal or epidermal immunisation. Further, the invention confers methods of attaching active ingredients, pharmaceutical formulations and vaccines to a surface by oily substances and the surfaces, pharmaceutical products and devices obtained by these methods. In particular, the present invention provides a device or pharmaceutical product for the attachment of vaccines to surfaces using oily substances that have at the same time an adjuvant effect.
    Type: Application
    Filed: September 23, 2014
    Publication date: August 11, 2016
    Inventors: Peter LELL, Gerhard WINTER, Julia ENGERT, Elas ETZL
  • Patent number: 9238021
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: January 19, 2016
    Assignee: Medigene AG
    Inventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
  • Patent number: 9233067
    Abstract: The present invention relates to a method of producing and loading silk particles, preferably spider silk particles, with a compound. In particular, the present invention provides a novel two step method for loading silk particles, preferably spider silk particles, with small and water-soluble compounds. Also disclosed are silk particles, preferably spider silk particles, loaded with at least one compound which are eminently suited as carriers for controlled and sustained delivery applications. Furthermore, the invention relates to pharmaceutical or cosmetic compositions comprising said silk particles, preferably spider silk particles, and a pharmaceutically active compound or cosmetic compound for controlled and sustained release. The present invention is also directed to silk particles, preferably spider silk particles, loaded with a compound obtainable by the method according to the invention.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: January 12, 2016
    Assignee: Amsilk GmbH
    Inventors: Andreas Lammel, Thomas Scheibel, Martin Schwab, Gerhard Winter, Markus Hofer, Julia Myschik
  • Publication number: 20150183863
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: June 19, 2014
    Publication date: July 2, 2015
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20150166648
    Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: June 5, 2014
    Publication date: June 18, 2015
    Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
  • Patent number: 9029046
    Abstract: One embodiment disclosed includes a product comprising: a fuel cell component comprising a substrate and a first coating overlying the substrate, the coating comprising a compound comprising at least one Si—O group, at least one polar group and at least one group including a saturated or unsaturated carbon chain.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: May 12, 2015
    Assignee: GM Global Technology Operations LLC
    Inventors: Gerhard Winter, Gayatri Vyas Dadheech, Thomas A. Trabold, Reena L. Datta
  • Patent number: 8940873
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 27, 2015
    Assignee: AbbVie Inc.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20140371292
    Abstract: The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase.
    Type: Application
    Filed: August 10, 2012
    Publication date: December 18, 2014
    Applicant: Ludwig-Maximilians-Universitat Munchen
    Inventors: Ahmed Besheer, Matthaus Noga, Gerhard Winter, Ernst Wagner, Daniel Edinger
  • Publication number: 20140248274
    Abstract: The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilisate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: ROCHE DIAGNOSTICS GMBH
    Inventors: Georg KALLMEYER, Gerhard WINTER, Christian KLESSEN, Heinrich WOOG
  • Patent number: 8822655
    Abstract: Herein is reported a tangential flow filtration method with a pre-filtration solute concentration adjustment in order to ensure a defined concentration of the components of the solution after tangential flow filtration.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: September 2, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
  • Publication number: 20140205657
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 24, 2014
    Applicant: MEDIGENE AG
    Inventors: Carsten MUNDUS, Christian WELZ, Oliver SCHRAMEL, Heinrich HAAS, Thomas FICHERT, Brita SCHULZE, Toralf PEYMANN, Uwe MICHAELIS, Michael TEIFEL, Friedrich GRUBER, Gerhard WINTER
  • Patent number: 8772458
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 8, 2014
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Anette Koenigsdorfer, Stefan Gottschalk, Hans-Juergen Krause, Gerhard Winter, David W. Borhani, Wolfgang Fraunhofer
  • Patent number: 8758747
    Abstract: The invention concerns lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies which contain a sugar or an amino sugar, an amino acid and a surfactant as stabilizers. In addition the invention concerns a process for the production of this stable lyophilizate as well as the use of a sugar or amino sugar, an amino acid and a surfactant as stabilizers for therapeutic or diagnostic agents containing antibodies.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: June 24, 2014
    Assignee: Roche Diagnostics GmbH
    Inventors: Georg Kallmeyer, Gerhard Winter, Christian Klessen, Heinrich Woog